It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Introduction
Cardiovascular disease (CVD) is the leading cause of mortality in type 1 diabetes (T1D). However, there is a need for daily practice tools for identifying those more prone to suffer from these events. We aimed to assess the relationships between nuclear magnetic resonance (1H NMR)-based lipidomic analysis and several CVD risk variables (including preclinical carotid atherosclerosis) in individuals with T1D at high risk.
Methods
We included patients with T1D without CVD, with at least one of the following: age ≥ 40 years, diabetic kidney disease, or ≥ 10 years of evolution with another risk factor. The presence of plaque (intima-media thickness > 1.5 mm) was determined by standardized ultrasonography protocol. Lipidomic analysis was performed by 1H NMR. Bivariate and multivariate-adjusted differences in 1H NMR lipidomics were evaluated.
Results
We included n = 131 participants (49.6% female, age 46.4 ± 10.3 years, diabetes duration 27.0 ± 9.5 years, 47.3% on statins). Carotid plaques were present in 28.2% of the individuals (n = 12, with ≥ 3 plaques). Glucose (HbA1c), anthropometric (body mass index and waist circumference), and insulin resistance-related (fatty liver index and estimated glucose disposal rate) variables were those most associated with 1H NMR-derived lipidomic analysis (p < 0.01 for all). Regarding preclinical atherosclerosis, sphingomyelin was independently associated with carotid plaque presence (for 0.1 mmol/L increase, OR 0.50 [0.28–0.86]; p = 0.013), even after adjusting for age, sex, hypertension, statin use, mean 5-year HbA1c and diabetes duration. Furthermore, linoleic acid and ω-6 fatty acids remained independently associated with higher plaque burden (≥ 3 plaques) in multivariate models (0.17 [0.03–0.93] and 0.27 [0.07–0.97], respectively; p < 0.05 for both).
Conclusion
In our preliminary study of individuals with T1D at high risk, several 1H NMR-derived lipidomic parameters were independently associated with preclinical atherosclerosis. Specifically, ω-6 fatty acids and linoleic acid seem promising for identifying those with higher plaque burden.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Hospital Clínic, Diabetes Unit, Endocrinology and Nutrition Department, Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413)
2 Hospital Clínic, Diabetes Unit, Endocrinology and Nutrition Department, Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413); Instituto de Salud Carlos III (ISCIII), Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427); Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413)
3 Hospital Universitari Mútua de Terrassa, Endocrinology and Nutrition Department, Terrassa, Spain (GRID:grid.414875.b) (ISNI:0000 0004 1794 4956)
4 Hospital Clínic, Diabetes Unit, Endocrinology and Nutrition Department, Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413); Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413); Instituto de Salud Carlos III (ISCIII), Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
5 Hospital Clínic, Diabetes Unit, Endocrinology and Nutrition Department, Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413); Althaia University Health Network, Endocrinology and Nutrition Department, Manresa, Spain (GRID:grid.488391.f) (ISNI:0000 0004 0426 7378)
6 Hospital Clínic, Diabetes Unit, Endocrinology and Nutrition Department, Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413); Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413)
7 Hospital Clínic, Diabetes Unit, Endocrinology and Nutrition Department, Barcelona, Spain (GRID:grid.410458.c) (ISNI:0000 0000 9635 9413); Instituto de Salud Carlos III (ISCIII), Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)